Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jueling Mingmu Decoction and Ranibizumab for Macular Cystoid Edema
NCT06234514Phase 4Completed
- Sponsor
- Dongyang People's Hospital
- Start
- Jan 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Jueling Mingmu decoction in cystoid macular edema (CME) (2 arms), sponsored by Dongyang People's Hospital. Primary endpoint: Mean number of injections at 48 weeks. Started Jan 2023; status: completed.
02
Drugs
Jueling Mingmu decoction
03
Conditions
cystoid macular edema (CME)
Beyond the preview
Go deeper on NCT06234514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234514.